Editas Medicine (EDIT) Notes Payables (2016 - 2017)
Editas Medicine (EDIT) reported Notes Payables of $7.5 million for Q4 2017, down 25.0% year-over-year from $10.0 million in Q4 2016, and down 50.0% quarter-over-quarter from $15.0 million in Q2 2017.
Editas Medicine (EDIT) Notes Payables (2016 - 2017) Analysis & Trends
Editas Medicine (EDIT) has 2 years of Notes Payables data on file, last reported at $7.5 million in Q4 2017.
- Notes Payables for Q4 2017 came in at $7.5 million, down 25.0% year-over-year; the trailing twelve-month figure through Dec 2017 was $7.5 million (down 25.0% YoY), and the FY2017 annual result was $7.5 million, down 25.0% from the prior year.
- Notes Payables declined to $7.5 million in Q4 2017 per EDIT's latest filing, from $15.0 million in the prior quarter.
- Over five years, Notes Payables peaked at $15.0 million in Q1 2017 and troughed at $7.5 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 7.50 Mn |
| Jun 30, 2017 | 15.00 Mn |
| Mar 31, 2017 | 15.00 Mn |
| Dec 31, 2016 | 10.00 Mn |